EBV Specific Cytotoxic T-Lymphocytes

Developed for: Hodgkins lymphoma · nasopharyngeal carcinoma · non-Hodgkin lymphoma
Investigated by: Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · The Methodist Hospital Research Institute · M.D. Anderson Cancer Center

today NCT00953420 · Ph 2 NCT00058773 · Ph 1

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00058773	Jan 1996 → Apr 2002	Hodgkins lymphoma, non-Hodgkin lymphoma	Baylor College of Medicine	Terminated	No outcome recorded
Phase 21 trial
Phase 2	NCT00953420	Nov 2009 → Jun 2014	nasopharyngeal carcinoma	Baylor College of Medicine	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	EBV-specific cytotoxic T lymphocytes	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00953420 ↗ 1 NCT00058773 ↗
Action	Deplete	“This stimulation will train the T cells to kill EBV infected cells” NCT00058773 ↗
Modality	Cell therapy	“These cells are grown in the laboratory and taught to recognize and attack EBV infected cells.” NCT00953420 ↗
Route	Intravenous	“EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.” NCT00058773 ↗